UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
REPROS THERAPEUTICS INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $0.001 PAR VALUE PER SHARE
--------------------------------------------------------------------------------
(Title of Class of Securities)
98975L108
--------------------------------------------------------------------------------
(CUSIP Number)
October 17, 2006
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
13G is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 98975L108
--------------------------------------------------------------------------------
(1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons
(entities only):
Xmark Opportunity Partners, LLC
20-2052197
--------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
--------------------------------------------------------------------------------
(3) SEC Use Only
--------------------------------------------------------------------------------
(4) Citizenship or Place of Organization: Delaware, United States
--------------------------------------------------------------------------------
Number of Shares Beneficially Owned by
Each Reporting Person With (5) Sole Voting Power: 698,739**
-------------------------------------
(6) Shared Voting Power: **
-------------------------------------
(7) Sole Dispositive Power: 698,739**
-------------------------------------
(8) Shared Dispositive Power: **
-------------------------------------
--------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person:
698,739**
--------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions): **
--------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9): 6.9%**
--------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions): IA
--------------------------------------------------------------------------------
** Xmark Opportunity Partners, LLC ("Opportunity Partners") is the sole member
of the investment manager of Xmark Opportunity Fund, L.P., a Delaware limited
partnership ("Opportunity LP"), and Xmark Opportunity Fund, Ltd., a Cayman
Islands exempted company ("Opportunity Ltd"), and, as such, possesses sole power
to vote and direct the disposition of all securities of Repros Therapeutics
Inc., a Delaware corporation (the "Company"), held by Opportunity LP and
Opportunity Ltd. Opportunity Partners is the investment manager of Xmark JV
Investment Partners, LLC, a Delaware limited liability company ("JV Partners"),
and, as such, possesses sole power to vote and direct the disposition of all
securities of the Company held by JV Partners. David C. Cavalier and Mitchell
D. Kaye, the Chief Operating Officer and Chief Executive Officer, respectively,
of Xmark Capital Partners, LLC, the Managing Member of Opportunity Partners,
share voting and investment power with respect to all securities beneficially
owned by Opportunity Partners.
As of October 17, 2006, Opportunity LP held 130,478 common shares, $0.001 par
value per share ("Common Shares"), of the Company, Opportunity Ltd held 243,271
Common Shares of the Company and JV Partners held 324,990 Common Shares of the
Company.
Based on information from the Company, as of October 17, 2006, there were
10,150,962 Common Shares of the Company issued and outstanding. As a result of
the foregoing, for purposes of Reg. Section 240.13d-3, Opportunity Partners is
deemed to beneficially own 698,739 Common Shares of the Company, or 6.9% of the
Common Shares of the Company deemed issued and outstanding as of October 17,
2006. Opportunity Partners' interest in the securities reported herein is
limited to the extent of its pecuniary interest in Opportunity LP, Opportunity
Ltd and JV Partners, if any.
Item 1(a). Name Of Issuer: Repros Therapeutics Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
2408 Timberloch Place, Suite B-7
The Woodlands, TX 77380
Item 2(a). Name of Person Filing:
Xmark Opportunity Partners, LLC
Item 2(b). Address of Principal Business Office or, if None, Residence:
301 Tresser Boulevard, Suite 1320
Stamford, CT 06901
Item 2(c). Citizenship:
Xmark Opportunity Partners, LLC is a Delaware limited liability
company.
Item 2(d). Title of Class of Securities: Common Stock, $0.001 par value
per share
Item 2(e). CUSIP No.: 98975L108
Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
240.13d-2(b) or (c), check whether the Person Filing is a:
Not Applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:
698,739**
(b) Percent of Class:
6.9%**
(c) Number of Shares as to which the person has:
(i) sole power to vote or to direct the vote 698,739**
(ii) shared power to vote or to direct the vote **
(iii) sole power to dispose or to direct the
disposition of 698,739**
(iv) shared power to dispose or to direct the
disposition of **
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the owner of more than five
percent of the class of securities, check the following: [ ].
Item 6. Ownership of More Than Five Percent on Behalf of Another Person
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company or Control
Person
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
-------------------
** Xmark Opportunity Partners, LLC ("Opportunity Partners") is the sole member
of the investment manager of Xmark Opportunity Fund, L.P., a Delaware limited
partnership ("Opportunity LP"), and Xmark Opportunity Fund, Ltd., a Cayman
Islands exempted company ("Opportunity Ltd"), and, as such, possesses sole power
to vote and direct the disposition of all securities of Repros Therapeutics
Inc., a Delaware corporation (the "Company"), held by Opportunity LP and
Opportunity Ltd. Opportunity Partners is the investment manager of Xmark JV
Investment Partners, LLC, a Delaware limited liability company ("JV Partners"),
and, as such, possesses sole power to vote and direct the disposition of all
securities of the Company held by JV Partners. David C. Cavalier and Mitchell
D. Kaye, the Chief Operating Officer and Chief Executive Officer, respectively,
of Xmark Capital Partners, LLC, the Managing Member of Opportunity Partners,
share voting and investment power with respect to all securities beneficially
owned by Opportunity Partners.
As of October 17, 2006, Opportunity LP held 130,478 common shares, $0.001 par
value per share ("Common Shares"), of the Company, Opportunity Ltd held 243,271
Common Shares of the Company and JV Partners held 324,990 Common Shares of the
Company.
Based on information from the Company, as of October 17, 2006, there were
10,150,962 Common Shares of the Company issued and outstanding. As a result of
the foregoing, for purposes of Reg. Section 240.13d-3, Opportunity Partners is
deemed to beneficially own 698,739 Common Shares of the Company, or 6.9% of the
Common Shares of the Company deemed issued and outstanding as of October 17,
2006. Opportunity Partners' interest in the securities reported herein is
limited to the extent of its pecuniary interest in Opportunity LP, Opportunity
Ltd and JV Partners, if any.
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
October 18, 2006
XMARK OPPORTUNITY PARTNERS, LLC
By: XMARK CAPITAL PARTNERS, LLC,
its Managing Member
By: /s/ Mitchell D. Kaye
-------------------------------
Name: Mitchell D. Kaye
Title: Chief Executive Officer
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001)